Citations

Clear

554 citation(s) found for "Li, Gerald".

Complications following pediatric cranioplasty after decompressive craniectomy: a multicenter retrospective study
Rocque, Brandon G. , Agee, Bonita S. , Thompson, Eric M. , Piedra, Mark, Baird, Lissa , Greene, Stephanie , Deibert, Christopher P., Hankinson, Todd C. , Lew, Sean M. , Iskandar, Bermans J. , Bragg, Taryn, Frim, David M. , Gupta, Nalin , Auguste, Kurtis I. , Nikas, Dimitrios C., Vassilyadi, Michael, Muh, Carrie R. , Wetjen, Nicholas M. , Lam, Sandi , Selden, Nathan R. W. , Grant, Gerald A. , Muh, Carrie R

Mayo Clinic

Journal of Neurosurgery: Pediatrics | June 8, 2018 | Volume: 22 | Issue: 3 | Pages: 225-232

10.3171/2018.3.peds17234 | PMID 29882736 Get It

OBJECTIVEIn children, the repair of skull defects arising from decompressive craniectomy presents a unique set of challenges. Single-center studies have identified different risk factors for the common complications of cranioplasty resorption and infection. The goal of the present study was to determine the risk factors for bone resorption and infection after pediatric cranioplasty.METHODSThe authors conducted a multicenter retrospective case study that included all patients who underwent cranioplasty to correct a skull defect arising from a decompressive craniectomy at 13 centers between 2000 and 2011 and were less than 19 years old at the time of cranioplasty. Prior systematic review of the literature along with expert opinion guided the selection of variables to be collected. These included: indication for craniectomy; history of abusive head trauma; method of bone storage; method of bone fixation; use of drains; size of bone graft; presence of other implants, including ventriculoperitoneal (VP) shunt; presence of fluid collections; age at craniectomy; and time between craniectomy and cranioplasty.RESULTSA total of 359 patients met the inclusion criteria. The patients’ mean age was 8.4 years, and 51.5% were female. Thirty-eight cases (10.5%) were complicated by infection. In multivariate analysis, presence of a cranial implant (primarily VP shunt) (OR 2.41, 95% CI 1.17–4.98), presence of gastrostomy (OR 2.44, 95% CI 1.03–5.79), and ventilator dependence (OR 8.45, 95% CI 1.10–65.08) were significant risk factors for cranioplasty infection. No other variable was associated with infection.Of the 240 patients who underwent a cranioplasty with bone graft, 21.7% showed bone resorption significant enough to warrant repeat surgical intervention. The most important predictor of cranioplasty bone resorption was age at the time of cranioplasty. For every month of increased age the risk of bone flap resorption decreased by 1% (OR 0.99, 95% CI 0.98–0.99, p < 0.001). Other risk factors for resorption in multivariate models were the use of external ventricular drains and lumbar shunts.CONCLUSIONSThis is the largest study of pediatric cranioplasty outcomes performed to date. Analysis included variables found to be significant in previous retrospective reports. Presence of a cranial implant such as VP shunt is the most significant risk factor for cranioplasty infection, whereas younger age at cranioplasty is the dominant risk factor for bone resorption.
1080 The Collaborative Care Visit Model: A New Way to Provide Ongoing Care Targeted to Long-Term Stable Positive Airway Pressure Users
Moore, Wendy , Burr, L E, McNamara, Sara, Clark, Peter, Peine, N A, Finstuen, Thomas, Herold, Daniel L., Brown, Vicki, Warner, Christopher H. , Trapp, Gerald, Olson, Eric J. , Auger, R. Robert , Louis, Erik K. St. , Junna, Mithri R. , St Louis, E K , Herold, Daniel L. , Lipford, Melissa C.

Mayo Clinic

Sleep | April 27, 2018 | Volume: 41 | Issue: suppl_1 | Pages: A401-A401

10.1093/sleep/zsy061.1079 Get It

Growth and alignment of the pediatric subaxial cervical spine following rigid instrumentation and fusion: a multicenter study of the Pediatric Craniocervical Society
Goldstein, Hannah E. , Neira, Justin A., Banu, Matei A. , Aldana, Philipp R. , Braga, Bruno P. , Brockmeyer, Douglas L. , DiLuna, Michael L. , Fulkerson, Daniel H. , Hankinson, Todd C. , Jea, Andrew, Lew, Sean M. , Limbrick, David D. , Martin, Jonathan E. , Rodriguez, Luis F. , Rozzelle, Curtis J. , Tuite, Gerald F. , Wetjen, Nicholas M. , Anderson, Richard C. E. , Limbrick, David D. , Pahys, Joshua M.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | April 20, 2018 | Volume: 22 | Issue: 1 | Pages: 81-88

10.3171/2018.1.peds17551 | PMID 29676682 Get It

OBJECTIVEThe long-term effects of surgical fusion on the growing subaxial cervical spine are largely unknown. Recent cross-sectional studies have demonstrated that there is continued growth of the cervical spine through the teenage years. The purpose of this multicenter study was to determine the effects of rigid instrumentation and fusion on the growing subaxial cervical spine by investigating vertical growth, cervical alignment, cervical curvature, and adjacent-segment instability over time.METHODSA total of 15 centers participated in this multi-institutional retrospective study. Cases involving children less than 16 years of age who underwent rigid instrumentation and fusion of the subaxial cervical spine (C-2 and T-1 inclusive) with at least 1 year of clinical and radiographic follow-up were investigated. Charts were reviewed for clinical data. Postoperative and most recent radiographs, CT, and MR images were used to measure vertical growth and assess alignment and stability.RESULTSEighty-one patients were included in the study, with a mean follow-up of 33 months. Ninety-five percent of patients had complete clinical resolution or significant improvement in symptoms. Postoperative cervical kyphosis was seen in only 4 patients (5%), and none developed a swan-neck deformity, unintended adjacent-level fusion, or instability. Of patients with at least 2 years of follow-up, 62% demonstrated growth across the fusion construct. On average, vertical growth was 79% (4-level constructs), 83% (3-level constructs), or 100% (2-level constructs) of expected growth. When comparing the group with continued vertical growth to the one without growth, there were no statistically significant differences in terms of age, sex, underlying etiology, surgical approach, or number of levels fused.CONCLUSIONSContinued vertical growth of the subaxial spine occurs in nearly two-thirds of children after rigid instrumentation and fusion of the subaxial spine. Failure of continued vertical growth is not associated with the patient’s age, sex, underlying etiology, number of levels fused, or surgical approach. Further studies are needed to understand this dichotomy and determine the long-term biomechanical effects of surgery on the growing pediatric cervical spine.
Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation
O’Brien, Emily C. , Holmes, DaJuanicia N. , Thomas, Laine , Kowey, Peter R. , Singer, Daniel E. , Ezekowitz, Michael D. , Ansell, Jack , Go, Alan S. , Reiffel, James A. , Piccini, Jonathan P. , Fonarow, Gregg C. , Allen, Larry A. , Gersh, Bernard J. , Naccarelli, Gerald V. , Chan, Paul S. , Mahaffey, Kenneth W. , Freeman, James V. , Peterson, Eric D. , Hylek, Elaine M.

Mayo Clinic

Circulation | April 20, 2018 | Volume: 138 | Issue: 9 | Pages: 889-897

10.1161/circulationaha.117.031354 | PMID 29678813 Get It

Background: Bleeding is commonly cited as a reason for stopping oral anticoagulants (OACs). Whether minor bleeding events (nuisance bleeding, NB) in patients with atrial fibrillation on OACs are associated with OAC discontinuation, major bleeding, and stroke/systemic embolism (SSE) is unknown. Methods: Within the ORBIT-AF prospective, outpatient registry (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation), we identified 6771 patients ≥18 years of age at 172 sites with atrial fibrillation and eligible follow-up visits. NB was ascertained from the medical record and was defined as minor bleeding that did not require medical attention (eg, bruising, hemorrhoidal bleeding). We used multivariable pooled logistic regression modeling to evaluate the associations between NB and major bleeding and SSE in the 180 days after documentation of NB. Our unit of analysis was the patient visit, occurring at ≈6-month intervals for a median of 1.5 years following enrollment. Changes in anticoagulation treatment satisfaction after NB were examined descriptively in a subset of patients. Results: The median age of the overall population was 75.0 (interquartile range, 67.0–81.0); 90.0% were white and 42.5% were female. Among 6771 patients (18 560 visits), n=1357 (20.0%) had documented NB, for an incidence rate of 14.8 events per 100 person-years. Over 96.4% of patients remained on OAC therapy after the NB event. Overall, 287 (4.3%) patients experienced major bleeding and 64 (0.96%) had a SSE event during follow-up. NB was not associated with a significant increased risk of major bleeding over 6 months in models adjusting for the ATRIA bleeding score (Anticoagulation and Risk Factors in Atrial Fibrillation) (odds ratio, 1.04; 95% confidence interval, 0.68–1.60; P =0.86). NB was also not associated with increased SSE risk over 6 months in models adjusting for the CHA 2 DS 2 -VASc risk score (odds ratio, 1.24; 95% confidence interval, 0.53–2.91; P =0.62). Conclusions: NB is common among patients with atrial fibrillation on OACs. However, NB was not associated with a higher risk of major bleeding or SSE over the next 6 months, suggesting its occurrence should not lead to changes in anticoagulation treatment strategies in OAC-treated patients. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01165710.
Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD)
Khoury, Paneez , Akuthota, Praveen , Ackerman, Steven J. , Arron, Joseph R. , Bochner, Bruce S. , Kahn, Jean‐Emmanuel , Fulkerson, Patricia C., Gleich, Gerald J. , Gopal-Srivastava, Rashmi, Jacobsen, Elizabeth A. , Leiferman, Kristen M, Francesca, Levi-Schaffer, Mathur, Sameer K. , Minnicozzi, Michael, Roufosse, Florence , Sable, Kathleen, Simon, Dagmar , Simon, Hans‐Uwe , Spencer, Lisa A. , Steinfeld, Jonathan , Wardlaw, Andrew J. , Weller, Peter F. , Bochner, Bruce S , Simon, Hans Uwe , Jacobsen, Elizabeth A , Collins, Margaret H. , Francesca, Levi-Schaffer, Prussin, Calman , Rothenberg, Marc E. , Wechsler, Michael E , Klion, Amy D.

Mayo Clinic

Journal of Leukocyte Biology | April 19, 2018 | Volume: 104 | Issue: 1 | Pages: 69-83

10.1002/jlb.5mr0118-028r | PMID 29672914 Get It

AbstractEosinophil-associated diseases (EADs) are rare, heterogeneous disorders characterized by the presence of eosinophils in tissues and/or peripheral blood resulting in immunopathology. The heterogeneity of tissue involvement, lack of sufficient animal models, technical challenges in working with eosinophils, and lack of standardized histopathologic approaches have hampered progress in basic research. Additionally, clinical trials and drug development for rare EADs are limited by the lack of primary and surrogate endpoints, biomarkers, and validated patient-reported outcomes. Researchers with expertise in eosinophil biology and eosinophil-related diseases reviewed the state of current eosinophil research, resources, progress, and unmet needs in the field since the 2012 meeting of the NIH Taskforce on the Research of Eosinophil-Associated Diseases (TREAD). RE-TREAD focused on gaps in basic science, translational, and clinical research on eosinophils and eosinophil-related pathogenesis. Improved recapitulation of human eosinophil biology and pathogenesis in murine models was felt to be of importance. Characterization of eosinophil phenotypes, the role of eosinophil subsets in tissues, identification of biomarkers of eosinophil activation and tissue load, and a better understanding of the role of eosinophils in human disease were prioritized. Finally, an unmet need for tools for use in clinical trials was emphasized. Histopathologic scoring, patient- and clinician-reported outcomes, and appropriate coding were deemed of paramount importance for research collaborations, drug development, and approval by regulatory agencies. Further exploration of the eosinophil genome, epigenome, and proteome was also encouraged. Although progress has been made since 2012, unmet needs in eosinophil research remain a priority.Review on eosinophil biology and eosinophil-related disorders (2012–2017) with a focus on continued unmet needs in eosinophil-associated diseases.
Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
Shrader, Peter, Pieper, Karen S. , Thomas, Laine , Ansell, Jack , Ezekowitz, Michael D. , Kowey, Peter R. , Reiffel, James A. , Singer, Daniel E. , Piccini, Jonathan P. , Investigators, the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF) II, Barrett, Tyler W. , Gazmuri, Raúl J. , Steinberg, Benjamin A. , Allen, Larry A. , Chan, Paul S. , Fonarow, Gregg C. , Freeman, James V. , Gersh, Bernard J. , Mahaffey, Kenneth W. , Naccarelli, Gerald V. , Peterson, Eric D. , Investigators, the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF) II, Gazmuri, Raúl J

Mayo Clinic

Journal of the American Heart Association | February 17, 2018 | Volume: 7 | Issue: 4 | Pages: No page available

10.1161/jaha.117.007633 | PMID 29453305 Get It

Background Non–vitamin K antagonist oral anticoagulants (NOACs) are indicated for stroke prevention in atrial fibrillation (AF) but require lower doses in certain patients. We sought to describe the frequency, appropriateness (according to Food and Drug Administration labeling), and outcomes of patients prescribed reduced doses of NOACs in community practice. Methods and Results We analyzed data from the ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II) registry, a prospective, national, observational registry of AF patients. Among 7925 AF patients receiving NOACs, we assessed patterns of use of reduced NOAC doses and associated cardiovascular and bleeding outcomes at median follow‐up of 1 year. Overall, 6636 patients (84%) received a NOAC at standard dose, which was consistent with US Food and Drug Administration labeling in 6376 (96%). Reduced NOAC dose was prescribed to 1289 (16% overall), which was consistent with Food and Drug Administration labeling in only 555 patients (43%). Compared with those whose NOAC dose was appropriately reduced, patients receiving inappropriate dose reductions were younger (median age 79 versus 84, P <0.0001) and had lower ORBIT bleeding risk scores (26% ≥4 versus 45%, P <0.0001). Compared with those appropriately receiving standard dosing, patients receiving inappropriately reduced‐dose NOACs had higher unadjusted rates of thromboembolic events (2.11 versus 1.35 events per 100 patient years, hazard ratio 1.56, 95% confidence interval 0.92‐2.67) and death (6.77 versus 2.60, hazard ratio 2.61, 95% confidence interval 1.86‐3.67). After adjustment, outcomes were not significantly different but tended to favor patients dosed appropriately. Conclusions The majority of dose reductions of NOACs in AF are inconsistent with US Food and Drug Administration recommendations. There appear to be opportunities to improve current NOAC dosing in community practice. Clinical Trial Registration URL: http://www.clinicaltrials.gov . Unique identifier: NCT01701817.
Granule-associated flavin adenine dinucleotide (FAD) is responsible for eosinophil autofluorescence
Mayeno, Arthur N., Hamann, Kimm J., Gleich, Gerald J.

Mayo Clinic

Journal of Leukocyte Biology | January 12, 2018 | Volume: 51 | Issue: 2 | Pages: 172-175

10.1002/jlb.51.2.172 | PMID 1431554 Get It

Abstract Unstained human eosinophils exhibit marked autofluorescence in comparison to other leukocytes due to a granule-associated fluorescent substance. Fluorescence spectroscopy of granule extracts reveals excitation maxima at ~380 and ~450 nm with a single emission at ~520, characteristic of flavins. The fluorescent material from eosinophil granule extracts was characterized by fluorescence, high-performance liquid chromatographic, and enzymatic analyses. First, acidification to pH 2.6 resulted in increased fluorescence, indicative of flavin adenine dinucleotide (FAD). Second, because flavin mononucleotide (FMN) and riboflavin cannot be distinguished by acidification, high-performance liquid chromatography was performed and revealed a predominance of FAD and smaller amounts (&lt;15%) of both FMN and riboflavin. Third, the presence of FAD was clearly demonstrated by reconstitution of the activity of d-amino acid oxidase, a FAD-dependent enzyme, when granule extracts were added to the apoenzyme. Thus, we have identified FAD as the predominant fluorophore in eosinophil granules. The small amounts of FMN and riboflavin detected may result from the hydrolysis of FAD under the acidic conditions of granule extraction. Because fluorescent material is deposited onto target cells by eosinophils, it is possible that granule-associated flavoproteins may act as a source of hydrogen peroxide and/or superoxide, which, in conjunction with eosinophil peroxidase, could yield potent cytotoxic agents.
Eosinophil viability during immunoglobulin-induced degranulation
Weiler, Catherine R., Kita, Hirohito , Hukee, Margaret J., Gleich, Gerald J. , Kita, H

Mayo Clinic

Journal of Leukocyte Biology | January 12, 2018 | Volume: 60 | Issue: 4 | Pages: 493-501

10.1002/jlb.60.4.493 | PMID 8864134 Get It

Abstract Eosinophil adhesion and degranulation appear to be associated with cell death. Eosinophils bound avidly and degranulated with secretory immunoglobulin A (slgA)- and IgG-coupled Sepharose 4B beads but bound poorly and did not degranulate with ovalbumin beads. Through the use of dye staining, we found that about 50% of the bound eosinophils were dead by 4 h, regardless of the protein coating. Colchicine and reduced calcium concentration inhibited binding to beads and eosinophil degranulation in a concentration-dependent manner but did not decrease the percentages of dead bound eosinophils. Electron microscopy showed that eosinophils bound to and spread over bead surfaces. Typical granule exocytosis with release of membrane-free granules occurred in about 20% of bound eosinophils. Eosinophil degeneration and lysis with release of membrane-coated granules occurred in about 50% of bound eosinophils; often only membrane-bound granules were present. Therefore, bound eosinophils degranulate both by classical exocytosis and by release after cytolytic degeneration. By increasing the numbers of bound cells, both IgG and sIgA increase the numbers of dying cells.
Reactivity of monoclonal antibodies EG1 and EG2 with eosinophils and their granule proteins
Nakajima, Hirokazu, Loegering, David A., Kita, Hirohito , Kephart, Gail M., Gleich, Gerald J. , Kita, H

Mayo Clinic

Journal of Leukocyte Biology | January 12, 2018 | Volume: 66 | Issue: 3 | Pages: 447-454

10.1002/jlb.66.3.447 | PMID 10496315 Get It

Abstract Use of the murine monoclonal antibodies EG1 and EG2 has been based on the assumption that EG2 recognizes activated eosinophils. We examined the reactivity of EG1 and EG2 with eosinophil cationic protein (ECP), eosinophil-derived neurotoxin (EDN), and stimulated and nonstimulated eosinophils from normal donors. By radioimmunoassay, EG1 recognized only ECP, whereas EG2 recognized both ECP and EDN. By Western blot, EG1 reacted with ECP, EG2 reacted with both ECP and EDN, but EG2 could not distinguish between lysates of stimulated and nonstimulated eosinophils. By immunofluorescence, EG1 and EG2 at 20 μg/mL stained 95–100% of nonstimulated eosinophils, regardless of fixative; EG1 and EG2 at 0.1 μg/mL stained 61–90% of acetone- and paraformaldehyde-fixed and only 5–21% of methanol-fixed nonstimulated eosinophils. Thus, the reactivity of EG1 and EG2 with eosinophils depends on the method of fixation and antibody concentration; and EG2, in contrast to previous reports, cannot reliably discriminate between resting and activated eosinophils. J. Leukoc. Biol. 66: 447–454; 1999.